BS BSX Boston Scientific Loading... : Bullish and Bearish Analyst Opinions

The 'extra week' in fiscal Q1 contributed approximately $570 million, or 670 bps, to revenue growth, but even excluding that, underlying growth was the strongest in nearly 8 years, indicating robust organic demand. — This indicates strong broad-based market demand across Medtronic's portfolio, not just one-off tailwinds.

Watch surgical and electrophysiology med-tech names

Multiple financial institutions have issued updates to their price targets for a wide range.

BTIG lowers its price target on Boston Scientific Corporation to 60 dollars from 65 dollars.

Reports Boston Scientific's outlook cut and pending restructuring, no directional view.

Boston Scientific executive says the company expects earnings and revenue growth to improve.

Boston Scientific executive says the company now expects the second half of 2026 to be more.

Management's guidance tone is clearly deteriorating due to expected continued pressure in EP and Watchman markets through 2027, leading to below-average growth and limited EPS expansion.

Boston Scientific reported Q2 adjusted EPS of 86 cents on net sales of 5.44 billion dollars.

Boston Scientific beats Q2 2026 earnings estimates but guides Q3 and full-year below consensus.

Boston Scientific reported second quarter 2026 net sales of 5.442 billion dollars with GAAP EPS.

Boston Scientific reported Q2 adjusted EPS of 86 cents beating estimates of 83 cents on net.

Boston Scientific cheap medical devices leader.

BSX has a TRR (TTM) of 1.099, exceeding the 2× S&P TRR (TTM) threshold of 1.0736, and its FWD TRR of 1.188 is close to the 2× FWD threshold of 1.2794. This suggests BSX offers a favorable risk/reward under John Neff’s low-P/E framework, combining moderate growth (15.6% EPS CAGR) with no dividend, but a low forward P/E (~13.13). The author flags BSX as the most attractive among the six names screened, but the edge is narrow and the stock has already moved up slightly, warranting monitoring rather than an immediate buy. Growth assumptions (15.6% EPS CAGR) may prove optimistic; the TRR ratio could fall below the 2× threshold if the stock price rises further or earnings disappoint; the method is backward-looking and may miss industry-specific risks.

Boston Scientific is down 50% this year after trimming 2026 sales growth guidance from 10% to 8%—a small adjustment for a massive selloff. The company remains well-managed with leading ablation products and a big buyback program; the 6% free-cash-flow yield and 13x forward earnings are deeply discounted. The market’s overreaction to a minor guidance tweak creates the most compelling value in the medtech sector. Slower adoption of new products; further procedure volume declines; debt or buyback execution risk.

The author advises against selling into deep losses and outlines a watchlist for potential tech.

Electrophysiology share inflection: Volt 2.0 goes from limited to full U.S. market release in Q3, and European EP sales grew over 20% on Volt/TactiFlex Duo rollout. — PFA competition is shifting; Abbott's launch momentum and mapping integration threaten the leading EP players' share in the highest-growth ablation category.

JNJ's electrophysiology growth was depressed ~400bps due to inventory destocking in China, suggesting a broader channel correction that may affect peers with China exposure. — If this is an industry-wide destocking, other medtech companies (Boston Scientific, Medtronic) may similarly see an EP growth headwind in coming quarters, beyond just JNJ.

BSX trades at $44, down from $90 in January, with Value Line estimating EPS of $3.25 this year and $3.50 next year (P/E ~13.5x), and the company completed an $2B ASR at ~$53/share. The market overreacted to the Penumbra acquisition and debt concerns; if PEN shareholders take cash (as implied by the stock drop), BSX avoids dilution and can use strong cash flows to de-lever, while EPS continues to grow. Buying BSX at a 13-14x forward P/E with double-digit EPS growth and a management team that aggressively repurchases shares provides a margin of safety and upside potential over the medium to long term. Integration of Penumbra could underperform; debt load from the $14.5B acquisition may pressure margins or trigger downgrades; sector rotation away from medtech could keep the stock depressed.

Medical devices are in a deep funk.

BSX is a Fast Grower with a PEG ratio of 0.59 and trades 24% below the author’s calculated fair value. The Soros “Panic” signal indicates market sentiment is irrationally negative, creating a buying opportunity when fundamentals remain strong. Lynch’s cheap + Soros’ bearish sentiment combination historically precedes mean reversion; BSX offers a margin of safety with growth tailwinds. Medical device regulatory setbacks, slower revenue growth, or a broader healthcare downturn could invalidate the thesis.

BSX trades at ~$57 vs Morningstar fair value of $81 and CFRA $67.63; EPS CAGR estimated 11-16% over next 5 years; CEO Mahoney has driven 16% EPS growth since 2010 with 85% accuracy. Valuation gap (discount to fair value) combined with strong product moats (PFA, WATCHMAN) and a proven management turnaround creates a buying opportunity. BSX is undervalued relative to its historical and projected earnings power, with catalysts from new product cycles and a long-tenured CEO. Competition from JNJ and Medtronic eroding PFA market share (projected drop from 58% to 48% by 2026); execution hiccups and recent guidance down; sector becoming capex-heavy and binary.

SEC FOIA logs reveal ongoing investigations for listed companies.

Bearish view on BSX expecting stock decline on CEO retirement catalyst in ~2 years.

Bearish view on BSX as CEO's $15M insider sale before a blackout period signals bearish.

The tweet implies insider selling by BSX's CEO before a blackout period.

Within Ecolab's life sciences business, bioprocessing sales more than doubled in Q1. — Indicates strong demand for biologic manufacturing capacity, benefiting pure-play single-use tech suppliers as they ramp.

Bearish view on BSX as the sharp +9% squeeze is unsustainable and signals a negative reversal.

Boston Scientific wait for bottom

Management guided down full-year revenue and EPS growth, citing share loss in EP, decelerating standalone Watchman cases, and challenges in urology.